Ignite Creation Date:
2025-12-25 @ 12:57 AM
Ignite Modification Date:
2026-02-27 @ 8:27 AM
Study NCT ID:
NCT02033993
Status:
COMPLETED
Last Update Posted:
2023-08-22
First Post:
2014-01-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
Sponsor:
Canadian Cancer Trials Group
Organization:
Study Overview
Official Title:
A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen.
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effects on urothelial cancer of nab-paclitaxel compared to paclitaxel to treat this disease.
This research is being done because currently there is no effective treatment for urothelial cancer that has progressed after prior chemotherapy.
This research is being done because currently there is no effective treatment for urothelial cancer that has progressed after prior chemotherapy.
Detailed Description:
Nab-paclitaxel is a formulation of the chemotherapeutic drug paclitaxel that is combined with a human protein called albumin. In Canada, nab-paclitaxel is currently approved for the treatment of metastatic breast cancer. This drug has been tested in other cancers and has shown promising activity in lung cancer, melanoma and pancreatic cancer. Information from research studies suggests that nab-paclitaxel may be a useful treatment for urothelial cancer.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: